Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

A Michael Lincoff; Jean-Claude Tardif; Gregory G Schwartz; Stephen J Nicholls; Lars Rydén; Bruce Neal; Klas Malmberg; Hans Wedel; John B Buse; Robert R Henry; Arlette Weichert; Ruth Cannata; Anders Svensson; Dietmar Volz; Diederick E Grobbee

首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

【24h】

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

机译：阿莱格达沙对2型糖尿病患者急性冠脉综合征后心血管结局的影响：AleCardio随机临床试验。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

clinicaltrials.gov Identifier: NCT01042769.

机译：Clinicaltrials.gov标识符：NCT01042769。

著录项

来源
《JAMA: the Journal of the American Medical Association》 |2014年第15期|共11页
作者
A Michael Lincoff; Jean-Claude Tardif; Gregory G Schwartz; Stephen J Nicholls; Lars Rydén; Bruce Neal; Klas Malmberg; Hans Wedel; John B Buse; Robert R Henry; Arlette Weichert; Ruth Cannata; Anders Svensson; Dietmar Volz; Diederick E Grobbee;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
入库时间 2022-08-19 15:39:04

相似文献

外文文献
中文文献
专利

1. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. [J] . A Michael Lincoff, Jean-Claude Tardif, Gregory G Schwartz, JAMA: the Journal of the American Medical Association . 2014,第15期

机译：患有2型糖尿病患者急性冠状动脉综合征后急性冠状动脉综合征后心血管结果的影响：Alecardio随机临床试验。
2. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial [J] . LincoffA.M., TardifJ.-C., NealB., The American heart journal . 2013,第3期

机译：评价双重过氧化物酶体增殖物激活受体α/γ激动剂阿格利他沙减少急性冠脉综合征和2型糖尿病患者的心血管事件：AleCardio试验的原理和设计
3. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. [J] . White WB, Bakris GL, Bergenstal RM, The American heart journal . 2011,第4期

机译：用2型糖尿病和急性冠状动脉综合征（EXAMINE）患者用alogliptIN相对于carE的心血管外科检查（EXAMINE）：二肽基肽酶4抑制剂alogliptin对2型糖尿病合并急性冠脉综合征的患者的心血管安全性研究。
4. Patients with acute coronary syndrome (ACS) and diabetes mellitus (DM) with intracoronary in - stent restenosis (one year observation) [C] . Dsjbek J, Ballys M, Gasior Z International Congress on Coronary Artery Disease . 2011

机译：患有急性冠状动脉综合征（ACS）和糖尿病（DM）的患者，具有颅内骨折（一年观察）
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome [O] . Xiaoteng Ma, Lisha Dong, Qiaoyu Shao, 2020

机译：甘油三酸酯葡萄糖指数预测2型糖尿病和急性冠脉综合征患者经皮冠状动脉介入治疗后的心血管结局
7. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus : the AleCardio randomized clinical trial [O] . Lincoff, A. Michael, Tardif, Jean-Claude, Schwartz, Gregory G., 2014

机译：阿格利他沙对2型糖尿病患者急性冠脉综合征后心血管结局的影响：AleCardio随机临床试验

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

摘要

著录项

相似文献

相关主题

期刊订阅